Skip to content

Study · Observational study · n = 3,850 · 2025

3 results

Impact of semaglutide 2.4 mg on healthcare resource utilization and medical costs in patients with atherosclerotic cardiovascular disease in the United States (SHINE-ASCVD).

Michalak W, Zhao Z, Faurby M, Alvarez S, Fitch A

Journal of medical economics12 Jul 2025Cited by 3 (Europe PMC)

PMID40579810 (opens in a new tab)DOI10.1080/13696998.2025.2526282 (opens in a new tab)PepBankPUB-40579810
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanObservational studyOther

    In patients with overweight or obesity and ASCVD, semaglutide 2.4 mg was associated with 22% lower mean medical costs in the year after initiation versus matched untreated controls.

    In plain wordsIn US patients with obesity and heart disease, semaglutide 2.4 mg was linked to 22% lower medical costs than in matched untreated patients.

    Peptide
    Semaglutide
    Outcome
    DecreaseAll-cause mean medical costs
    Study

    n = 3,850

    Comparator
    Semaglutide-untreated controls (propensity matched)
    Outcome group
    Healthcare costs and utilization · Cardiovascular
    Studied dose
    2.4 mgAs given in this study (human).

    Measurements

    Cost ratio
    0.78 ratio
    semaglutide 2.4 mg vs controls

    Source sentences

    Summary
    In the year following treatment initiation, semaglutide 2.4 mg was associated with 22% lower mean medical costs versus controls (-$4,639 per patient per year [PPPY]; cost ratio = 0.78, 95% confidence interval [CI] 0.67, 0.89)
    2 context sentences
    Summary · context
    This observational cohort study utilized Komodo's Healthcare Map and included patients with ov/ob and ≥1 diagnosis of ASCVD during the baseline period with ≥12 months of insurance coverage before and after the index date.
    Summary · context
    Semaglutide-untreated controls were randomly selected and 1:4 propensity score matched based on baseline demographics, clinical characteristics, medical costs, and HCRU.
  2. 02HumanObservational studyOther

    In patients with overweight or obesity and ASCVD, semaglutide 2.4 mg was associated with 65% lower inpatient costs versus matched untreated controls.

    In plain wordsIn US patients with obesity and heart disease, semaglutide 2.4 mg was linked to 65% lower inpatient costs than in matched untreated patients.

    Peptide
    Semaglutide
    Outcome
    DecreaseInpatient costs
    Study

    n = 3,850

    Comparator
    Semaglutide-untreated controls (propensity matched)
    Outcome group
    Healthcare costs and utilization · Cardiovascular
    Studied dose
    2.4 mgAs given in this study (human).

    Measurements

    Cost ratio
    0.35 ratio
    inpatient costs

    Source sentences

    Summary
    which were 65% lower than controls (-$3,593; cost ratio = 0.35 [95% CI 0.21, 0.49])
    2 context sentences
    Summary · context
    This observational cohort study utilized Komodo's Healthcare Map and included patients with ov/ob and ≥1 diagnosis of ASCVD during the baseline period with ≥12 months of insurance coverage before and after the index date.
    Summary · context
    Semaglutide-untreated controls were randomly selected and 1:4 propensity score matched based on baseline demographics, clinical characteristics, medical costs, and HCRU.
  3. 03HumanObservational studyOther

    In patients with overweight or obesity and ASCVD, semaglutide 2.4 mg was associated with a 48% lower inpatient visit rate versus matched untreated controls.

    In plain wordsIn US patients with obesity and heart disease, semaglutide 2.4 mg was linked to 48% fewer inpatient visits than in matched untreated patients.

    Peptide
    Semaglutide
    Outcome
    DecreaseInpatient visit rate
    Study

    n = 3,850

    Comparator
    Semaglutide-untreated controls (propensity matched)
    Outcome group
    Healthcare costs and utilization · Cardiovascular
    Studied dose
    2.4 mgAs given in this study (human).

    Measurements

    Rate ratio
    0.52 ratio
    inpatient visits

    Source sentences

    Summary
    along with a 48% lower inpatient visit rate (0.08 vs. 0.15; rate ratio = 0.52 [95% CI 0.34, 0.70]).
    2 context sentences
    Summary · context
    This observational cohort study utilized Komodo's Healthcare Map and included patients with ov/ob and ≥1 diagnosis of ASCVD during the baseline period with ≥12 months of insurance coverage before and after the index date.
    Summary · context
    Semaglutide-untreated controls were randomly selected and 1:4 propensity score matched based on baseline demographics, clinical characteristics, medical costs, and HCRU.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.